COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show
evidence of central nervous system (CNS) damage, predominantly ischaemic, in some …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Blood protein extravasation through a disrupted blood–brain barrier and innate immune
activation are hallmarks of neurological diseases and emerging therapeutic targets …

The treatment of multiple sclerosis has been transformed by the successful development of
immunotherapies that efficiently reduce disease activity and related clinical relapses during …

Oligodendrocytes generate multiple layers of myelin membrane around axons of the central
nervous system to enable fast and efficient nerve conduction. Until recently, saltatory nerve …

The blood coagulation protein fibrinogen is deposited in the brain in a wide range of
neurological diseases and traumatic injuries with blood–brain barrier (BBB) disruption …

Cerebrovascular alterations are a key feature of Alzheimer's disease (AD) pathogenesis.
However, whether vascular damage contributes to synaptic dysfunction and how it …

Tissue-tissue communication by endocrine factors is a vital mechanism for physiologic
homeostasis. A systems genetics analysis of transcriptomic and functional data from a cohort …

Fibrinogen is an abundant protein synthesized in the liver, present in human blood plasma
at concentrations ranging from 1.5-4 g/L in healthy individuals with a normal half-life of 3-5 …

Remyelination failure contributes to axonal loss and progression of disability in multiple
sclerosis. The failed repair process could be due to ongoing toxic neuroinflammation and to …